On September 11, 2020 Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, reported that Noridian, the Medicare Administrative Contractor (MAC) for Northern California, has finalized a final local coverage article (LCA) to provide Medicare benefits for serial use of the Signatera molecular residual disease (MRD) test in patients with a history of colorectal cancer (Press release, Natera, SEP 11, 2020, View Source [SID1234565033]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Noridian article is in line with the positive coverage determination issued by the CMS Molecular Diagnostics (MOLDX) program last week via Palmetto GBA and shares the same effective date of October 18th, 2020.